Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Z1OS
|
|||
Former ID |
DNCL002833
|
|||
Drug Name |
ARI-2243
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
Company |
Arisaph Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Modulator | [2] |
KEGG Pathway | Protein digestion and absorption | |||
NetPath Pathway | IL2 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028500) | |||
REF 2 | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.